157 related articles for article (PubMed ID: 32866625)
1. A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials.
Amiri-Kordestani L; Xie D; Tolaney SM; Bloomquist E; Tang S; Ibrahim A; Goldberg KB; Theoret MR; Pazdur R; Sridhara R; Winer EP; Beaver JA
Ann Oncol; 2020 Dec; 31(12):1704-1708. PubMed ID: 32866625
[TBL] [Abstract][Full Text] [Related]
2. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
3. Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.
Reeder-Hayes KE; Meyer AM; Hinton SP; Meng K; Carey LA; Dusetzina SB
J Clin Oncol; 2017 Oct; 35(29):3298-3305. PubMed ID: 28727517
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.
Hajjar A; Ergun MA; Alagoz O; Rampurwala M
PLoS One; 2019; 14(6):e0217778. PubMed ID: 31166995
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
Tolaney SM; Tayob N; Dang C; Yardley DA; Isakoff SJ; Valero V; Faggen M; Mulvey T; Bose R; Hu J; Weckstein D; Wolff AC; Reeder-Hayes K; Rugo HS; Ramaswamy B; Zuckerman D; Hart L; Gadi VK; Constantine M; Cheng K; Briccetti F; Schneider B; Garrett AM; Marcom K; Albain K; DeFusco P; Tung N; Ardman B; Nanda R; Jankowitz RC; Rimawi M; Abramson V; Pohlmann PR; Van Poznak C; Forero-Torres A; Liu M; Ruddy K; Zheng Y; Rosenberg SM; Gelber RD; Trippa L; Barry W; DeMeo M; Burstein H; Partridge A; Winer EP; Krop I
J Clin Oncol; 2021 Jul; 39(21):2375-2385. PubMed ID: 34077270
[TBL] [Abstract][Full Text] [Related]
7. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Untch M; von Minckwitz G; Gerber B; Schem C; Rezai M; Fasching PA; Tesch H; Eggemann H; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Loibl S;
J Clin Oncol; 2018 May; 36(13):1308-1316. PubMed ID: 29543566
[TBL] [Abstract][Full Text] [Related]
8. Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer.
Veitch Z; Khan OF; Tilley D; Ribnikar D; Kostaras X; King K; Tang P; Lupichuk S
J Natl Compr Canc Netw; 2019 Jan; 17(1):47-56. PubMed ID: 30659129
[No Abstract] [Full Text] [Related]
9. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
Shen Y; Fujii T; Ueno NT; Tripathy D; Fu N; Zhou H; Ning J; Xiao L
Breast Cancer Res Treat; 2019 Jan; 173(1):1-9. PubMed ID: 30242579
[TBL] [Abstract][Full Text] [Related]
10. Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Debien V; Marta GN; Agostinetto E; Sirico M; Jacobs F; Molinelli C; Moreau M; Paesmans M; De Giorgi U; Santoro A; Taylor D; Duhoux FP; Botticelli A; Barchiesi G; Speranza I; Lambertini M; Wildiers H; Azambuja E; Piccart M
Crit Rev Oncol Hematol; 2023 Oct; 190():104089. PubMed ID: 37562696
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Valero V; Forbes J; Pegram MD; Pienkowski T; Eiermann W; von Minckwitz G; Roche H; Martin M; Crown J; Mackey JR; Fumoleau P; Rolski J; Mrsic-Krmpotic Z; Jagiello-Gruszfeld A; Riva A; Buyse M; Taupin H; Sauter G; Press MF; Slamon DJ
J Clin Oncol; 2011 Jan; 29(2):149-56. PubMed ID: 21115860
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.
Rocque G; Onitilo A; Engel J; Pettke E; Boshoven A; Kim K; Rishi S; Waack B; Wisinski KB; Tevaarwerk A; Burkard ME
Breast Cancer Res Treat; 2012 Jan; 131(2):713-21. PubMed ID: 22065290
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
Hurvitz SA; Martin M; Jung KH; Huang CS; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Fasching PA; Afenjar K; Spera G; Lopez-Valverde V; Song C; Trask P; Boulet T; Sparano JA; Symmans WF; Thompson AM; Slamon D
J Clin Oncol; 2019 Sep; 37(25):2206-2216. PubMed ID: 31157583
[TBL] [Abstract][Full Text] [Related]
15. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.
Advani PP; Ballman KV; Dockter TJ; Colon-Otero G; Perez EA
J Clin Oncol; 2016 Feb; 34(6):581-7. PubMed ID: 26392097
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience.
Diker O; Aktas BY; Ak R; Koylu B; Bas O; Taban H; Guven DC; Olgun P; Kertmen N; Dizdar O; Oksuzoglu B; Aksoy S
Future Oncol; 2022 Jan; 18(3):323-331. PubMed ID: 34758639
[TBL] [Abstract][Full Text] [Related]
18. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
[TBL] [Abstract][Full Text] [Related]
19. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Ueno T; Masuda N; Sato N; Ohtani S; Yamamura J; Matsunami N; Kashiwaba M; Takano T; Takahashi M; Kaneko K; Ohno S; Morita S; Toi M
Jpn J Clin Oncol; 2020 Jan; 50(1):3-11. PubMed ID: 31821506
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer.
Howie LJ; Scher NS; Amiri-Kordestani L; Zhang L; King-Kallimanis BL; Choudhry Y; Schroeder J; Goldberg KB; Kluetz PG; Ibrahim A; Sridhara R; Blumenthal GM; Pazdur R; Beaver JA
Clin Cancer Res; 2019 May; 25(10):2949-2955. PubMed ID: 30552112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
